Prediction of calculated future cardiovascular disease by monocyte count in an asymptomatic population

Vascular Health and Risk Management

Volumn 4, Issue 1, 2008, Pages 177-187

  Waterhouse, Deirdre F ^a   Cahill, Ronan A ^b   Sheehan, Frances ^b   McCreery, C J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b Blackrock Clinic Ireland   (Ireland)

Author keywords

Asymptomatic population; Cardiovascular risk; Leukocyte; Monocyte; White cell count

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BASOPHIL; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FRACTIONATION; CHOLESTEROL BLOOD LEVEL; EXERCISE TEST; FEMALE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MONOCYTE COUNT; NEUTROPHIL COUNT; PHLEBOTOMY; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MASS SCREENING; MIDDLE AGED; MONOCYTES; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RISK ASSESSMENT;

EID: 41549150305     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2008.04.01.177     Document Type: Article

References (50)

1. Aktas MK, Ozduran V, Pothier CE, et al. 2004. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. JAMA, 292:1462-8.
2. Barron HV, Harr SD, Radford MJ, et al. 2001. The association between white blood cell count and acute myocardial infarction mortality in patients ≥ 65 years of age: findings from the cooperative cardiovascular project. J Am Coll Cardiol, 38:1654-61.
3. Conroy RM, Pyorala K, Fitzgerald AP, et al. 2003. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J, 24:987-1003.
4. Danesh J, Collins R, Appleby P, et al. 1998. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA, 279:1477-82.
5. Danesh J, Collins R, Peto R. 2000. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation, 102:1082-5.
6. Dragu R, Huri S, Zuckerman R, et al. 2006. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. Atherosclerosis, Dec 13; [Epub ahead of print].
7. Empana JP, Ducimetiere P, Arveiler D, et al. 2003. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J, 24:1903-11.
8. Falk E, Shah PK, Fuster V. 1995. Coronary plaque disruption. Circulation, 92:657-71.
9. Falk E. 2006. Pathogenesis of atherosclerosis. J Am Coll Cardiol, 47(8 Suppl):C7-12.
10. Folsom AR, Ma J, Eckfeldt JH, et al. 1995. Low serum albumin. Association with diabetes mellitus and other cardiovascular risk factors but not with prevalent cardiovascular disease or carotid artery intima-media thickness. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Ann Epidemiol, 5:186-91.
11. Folsom AR, Wu KY, Rosamond WD, et al. 1997. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 96:1102-8.
12. Gillum RF, Mussolino ME, Madans JH. 2005. Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary hart disease: the NHANES-I epidemiologic follow-up study. Ann Epidemiol, 15:266-71.
13. Grimm RH Jr, Neaton JD, Ludwig W 1985. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA, 254:1932-7.
14. Haim M, Boyko V, Goldbourt U, et al. 2004. Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease: the Bezafibrate Infarction Prevention Study. Arch Intern Med, 164:433-9.
15. Hansson GK. 2005. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 352:1685-95.
16. Haq IU, Ramsay LE, Yeo WW, et al. 1999. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart, 81:40-6.
17. Hense HW, Schulte H, Lowel H, et al. 2003. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J, 24:937-45.
18. Hoffman M, Blum A, Baruch R, et al. 2004. Leukocytes and coronary heart disease. Atherosclerosis, 172:1-6.
19. Horne BD, Anderson JL, John JM, et al. 2005. Intermountain Heart Collaborative Study Group: Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol, 45:1638-43.
20. James AL, Knuiman MW, Divitini ML, et al. 1999. Associations between white blood cell count, lung function, respiratory illness and mortality: the Busselton Health Study. Eur Respir J, 13:1115-19.
21. Kannel WB, Anderson K, Wilson PW. 1992. White blood cell count an cardiovascular disease: insights from the Framingham Study. JAMA, 267:1253-6.
22. Kirtane AJ, Bui A, Murphy SA, et al. 2004. Association of peripheral neutrophilia with adverse angiographic outcomes in ST-elevation myocardial infarction. Am J Cardiol, 93:532-6.
23. Kuller LH, Tracy RP, Shaten J, et al. 1996. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol, 144:537-47.
24. Lee CD, Folsom AR, Nieto FJ, et al. 2001. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis risk in communities study. Am J Epidemiol, 154:758-64.
25. Libby P. 1995. Molecular bases of the acute coronary syndromes. Circulation, 91:2844-50.
26. Libby P. 2002. Inflammation in atherosclerosis. Nature, 420:868-74.
27. Madjid M, Awan I, Willerson JT, et al. 2004. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol, 44:1945-56.
28. Margolis KL, Manson JE, Greenland P, et al. 2005. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med, 165:500-8.
29. Menotti A, Puddu PE, Lanti M. 2000. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J, 21:365-70.
30. McEwan P, Williams JE, Griffiths JD, et al. 2004. Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med, 21:318-23.
31. Nasir K, Guallar E, Navas-Acien A, et al. 2005. Relationship of monocyte count and peripheral arterial disease: results from the National Health and Nutrition Examination Survey 1999-2002. Arterioscler Tromb Vasc Biol, 25:1966-71.
32. Olivares R, Ducimetiere P, Claude JR. 1993. Monocyte count: a risk factor for coronary heart disease? Am J Epidemiol, 137:49-53.
33. Pearson TA, Mensah GA, Alexander RW, et al. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107:499-511.
34. Pepys MB, Berger A. 2001. The renaissance of C reactive protein. BMJ, 322:4-5.
35. Prentice RL, Szatrowski TP, Kato H, et al. 1982a. Leukocyte counts and cerebrovascular disease. J Chronic Dis, 35:703-1.
36. Prentice RL, Szatrowski TP, Fujikura T, et al. 1982b. Leukocyte counts and coronary heart disease in a Japanese cohort. Am J Epidemiol, 116:496-509.
37. Pyorala K. 2000. Assessment of coronary heart disease risk in populations with different levels of risk. Eur Heart J, 21:348-50.
38. Ridker PM. 1998. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J, 19:1-3.
39. Ross R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362:801-9.
40. Ross R. 1999. Atherosclerosis - an inflammatory disease. N Engl J Med, 340:115-26.
41. Roy D, Quiles J, Avanzas P, et al. 2006. A comparative study of markers of inflammation for the assessment of cardiovascular risk in patients presenting to the emergency department with acute chest pain suggestive of acute coronary syndrome. Int J Cardiol, 109:317-21.
42. Swirski FK, Libby P, Aikawa E, et al. 2007. Ly-6Chi monocytes dominate hypercholesteroleniia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest, 117:195-205.
43. Thomsen TF, McGee D, Davidsen M, et al. 2002. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Gtostrup Population Studies and Framingham Heart Study. Int J Epidemiol, 31:817-22.
44. Topol EJ, Lauer MS. 2003. The rudimentary phase of personalised medicine: coronary risk scores. Lancet, 362:1776-7.
45. Tracey RP. 1998. Inflarnmation in cardiovascular disease: cart, horse, or both? Circulation, 97:2000-2.
46. Weiss ST, Segal MR, Sparrow D, et al. 1995. Relation of FEV1 and peripheral blood leukocyte count to total mortality. The Normative Aging Study. Am J Epidemiol, 142:493-8; Discussion, 499-503.
47. Wheeler JG, Mussolino ME, Gillum RF, et al. 2004. Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals. Eur Heart J, 25:1287-92.
48. Wilson PW, D'Agostino RB. Levy D, et al. 1998. Prediction of coronary heart disease using risk factor categories. Circulation, 97:1837-47.
49. Yarnell JW, Baker IA, Sweetnam PM, et al. 1991. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation, 83:836-44.
50. Zalokar JB. 1983. Leukocyte counts and coronary heart disease in a Japanese cohort. Am J Epidemiol, 118:611-12.